These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 10609773

  • 1. Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer.
    Velpandian T, Gupta SK, Gupta YK, Agarwal HC, Biswas NR.
    J Ocul Pharmacol Ther; 1999 Dec; 15(6):505-11. PubMed ID: 10609773
    [Abstract] [Full Text] [Related]

  • 2. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS, Denton P, Osterhout GJ, Tuli S, O'Brien TP.
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [Abstract] [Full Text] [Related]

  • 3. Effect of diclofenac on ocular levels of ciprofloxacin and lomefloxacin in rabbits with endophthalmitis.
    Krustev SZ, Rusenova NV, Haritova AM.
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1459-62. PubMed ID: 23937580
    [Abstract] [Full Text] [Related]

  • 4. Comparison of topical lomefloxacin 0.3 per cent versus topical ciprofloxacin 0.3 per cent for the treatment of presumed bacterial corneal ulcers.
    Booranapong W, Kosrirukvongs P, Prabhasawat P, Srivannaboon S, Suttiprakarn P.
    J Med Assoc Thai; 2004 Mar; 87(3):246-54. PubMed ID: 15117040
    [Abstract] [Full Text] [Related]

  • 5. Ocular distribution of lomefloxacin 0.3% after a single instillation in the infected eye of pigmented rabbits.
    Elena PP, Jauch A.
    J Ocul Pharmacol Ther; 1997 Dec; 13(6):551-8. PubMed ID: 9436158
    [Abstract] [Full Text] [Related]

  • 6. Lomefloxacin is an effective treatment of experimental bacterial keratitis.
    Kowalski RP, Romanowski EG, Yates KA, Gordon YJ.
    Cornea; 2001 Apr; 20(3):306-8. PubMed ID: 11322421
    [Abstract] [Full Text] [Related]

  • 7. [Lomefloxacin in treatment of infectious eye diseases].
    Maĭchuk IuF, Vakhova ES, Kononenko LA.
    Antibiot Khimioter; 1998 Apr; 43(10):32-5. PubMed ID: 9825108
    [Abstract] [Full Text] [Related]

  • 8. Effect of propolis in the treatment of experimental Staphylococcus aureus keratitis in rabbits.
    Oksuz H, Duran N, Tamer C, Cetin M, Silici S.
    Ophthalmic Res; 2005 Apr; 37(6):328-34. PubMed ID: 16138004
    [Abstract] [Full Text] [Related]

  • 9. [Intraocular penetration of topical lomefloxacin in rabbit's eyes].
    Zhang Y, Chen Y, Chen Z.
    Zhonghua Yan Ke Za Zhi; 1998 May; 34(3):211-4. PubMed ID: 11877193
    [Abstract] [Full Text] [Related]

  • 10. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
    Jensen H, Zerouala C, Carrier M, Short B.
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Successful treatment of methicillin-resistant Staphylococcus aureus Keratitis with topical ciprofloxacin.
    Insler MS, Fish LA, Silbernagel J, Hobden JA, O'Callaghan RJ, Hill JM.
    Ophthalmology; 1991 Nov; 98(11):1690-2. PubMed ID: 1800931
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fluoroquinolones: place in ocular therapy.
    Smith A, Pennefather PM, Kaye SB, Hart CA.
    Drugs; 2001 Nov; 61(6):747-61. PubMed ID: 11398907
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification.
    Bucci FA.
    Am J Ophthalmol; 2004 Feb; 137(2):308-12. PubMed ID: 14962422
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ocular bioavailability of ciprofloxacin in sustained release formulations.
    Ke TL, Cagle G, Schlech B, Lorenzetti OJ, Mattern J.
    J Ocul Pharmacol Ther; 2001 Dec; 17(6):555-63. PubMed ID: 11777179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.